First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks

First Lady Jill Biden unveiled a significant milestone in the White House Initiative on Women’s Health Research by announcing $100 million in federal funding for research and development for women’s health. 

This move represents a crucial step in addressing the historical underfunding and lack of research into women’s health issues, a concern highlighted by Biden.

The funding stems from the Advanced Research Projects Agency for Health (ARPA-H), a component of the federal Department of Health and Human Services. 

The initiative marks a pivotal moment in advancing solutions to women’s health problems, the Washington Post noted, aiming to reshape the research landscape and secure increased funding.

President Joe Biden established the Advanced Research Projects Agency for Health in 2022 as part of his “unity agenda,” focusing on tackling health challenges. 

The newly announced ARPA-H Sprint for Women’s Health will kick off in the coming weeks, encouraging innovative ideas to propel groundbreaking research and development in women’s health.

During an appearance in Cambridge, Massachusetts, the First Lady emphasized the lack of awareness among women regarding their health due to historical underfunding in research. 

Have a look at the stocks:

Hologic Inc HOLX markets women’s diagnostics, including skeletal health and scanner systems and diagnostic products related to Sexually Transmitted Infections.

Daré Bioscience Inc DARE markets Xaciato (Clindamycin Phosphate) Vaginal Gel 2% indicated for bacterial vaginosis in females 12 years of age and older. The company also has several products under development for contraception, sexual & vaginal health, fertility, and menopause.

Aspira Women’s Health Inc AWH is focused on ovarian cancer diagnosis. The company developed OvaSuite, a blood test for ovarian cancer, to use with ultrasound checkups (OvaWATCH).

Organon Inc.’s OGN portfolio and pipeline are focused on bacterial vaginosis, breast cancer, contraception, endometriosis, fertility, hysterectomy, menopause, osteoporosis, polycystic ovarian syndrome, and postpartum hemorrhage.

Femasys Inc’s FEMY FemBloc permanent birth control in late-stage clinical development as the first and only non-surgical, in-office, permanent birth control method. Femasys’ FDA-approved FemaSeed Intratubal Insemination is an infertility treatment designed to deliver sperm directly where conception occurs.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jill Biden Photo By Gage Skidmore On Flickr